Insight

Aug 19, 2024, 10:29

New ELN classification of AML receiving less intense therapies

Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by Hartmut Döhner et al. published in Blood Journal.

“Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations”

Authors: Hartmut Döhner, Courtney DiNardo, Andrew Wei, Jianxiang Wang, Agnieszka Wierzbowska et al.

“Just out in Blood Journal – new ELN classification of AML receiving less intense therapies – we discuss this classification in our upcoming Blood Cancer Talks episode with Prof. Andrew Wei.”

Source: Eddie Cliff/X

Acute Myeloid Leukaemia Agnieszka Wierzbowska AML Andrew Wei Blood Cancer Talks Blood Journal cancer Courtney DiNardo Eddie Cliff Hartmut Döhner Jianxiang Wang OncoDaily Oncology Peter MacCallum Cancer Centre

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage